A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

Exclusion Criteria

• •History of significant systemic diseases (hematologic, renal, endocrine, pulmonary, GI, cardiac, hepatic, psychiatric, neurologic, infectious, allergic; except mild seasonal allergies).
• •Clinically significant ECG abnormalities.
• •Frequent headaches or migraines, and recurrent nausea or vomiting (over twice monthly).
• •Blood donation within 2 months.
• •Symptomatic or significant postural hypotension.
• •Drug hypersensitivity or significant allergies, including to study drugs.
• •History of drug/alcohol abuse.
• •Tobacco use within 3 months prior to Day 1.
• •History of Hepatitis B/C, TB, or invasive opportunistic infections.
• •Malignancy within 5 years (except treated non-metastatic skin cancer).
• •Adverse reaction to balinatunfib, moxifloxacin, or quinolones.
• •Any medication (except hormonal contraception/HRT) within 14 days or 5× half-life.
• •Biologics within 4 months prior.
• •Vaccines: non-live within 4 weeks, live within 3 months before or during study.
• •Current or recent participation in another interventional study within 30 days.
• •Positive for HBsAg, anti-HBc, anti-HCV, anti-HIV1/2.
• •Positive urine drug screen.
• •Positive alcohol breath test.
• •Positive urine cotinine test.
• •History of long QT syndrome.
• •Risk factors for TdP.
• •Moxifloxacin contraindications.
• •Low potassium (\<3.5 mmol/L).
• •Low magnesium (\<0.7 mmol/L).
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.